Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.
5 reports, 1 independent
Updated Sep 21
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
Related events
- Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.
- Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.
- The CEO of Truist Financial purchased company stock on September 21st, disclosing the insider transaction to the SEC.